| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Original article |
Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials
1 Cattedra di Ematologia, Università Cattolica S. Cuore, Rome; 2 Dipartimento di Biotecnologie cellulari ed Ematologia, Università "La Sapienza", Rome; 3 Centro Dati GIMEMA Dipartimento di Biotecnologie cellulari ed Ematologia, Università "La Sapienza", Rome; 4 Dipartimento di Epidemiologia e Biostatistica Istituto Superiore di Sanità, Rome; 5 U.O.A. di Ematologia, Ospedale SS: Antonio e Biagio, Alessandria; 6 Ematologia, Ospedale Generale Regionale, Bolzano; 7 Divisione di Ematologia, Ospedale Oncologico "A. Businco", Cagliari; 8 Divisione di Ematologia, Ospedale Regionale "A. Pugliese", Catanzaro; 9 Divisione di Ematologia, Policlinico di Careggi, Firenze; 10 Dipartimento di Scienze Mediche, Oncologiche e Radiologiche, Sezione di Medicina Interna, Oncologia ed Ematologia, Modena; 11 Sezione di Ematologia Clinica, Ospedale "S. Francesco", Nuoro; 12 Divisione di Ematologia, Ospedale "S. Carlo", Potenza; 13 Cattedra di Ematologia, Università di Tor Vergata, Rome, Italy
* Correspondence to: Professor L. Pagano, Department of Haematology, Catholic University, Largo Francesco Vito 1, I-00168 Roma, Italy. Tel: +39-0630154180; Fax: +39-063051343; Email: lpagano{at}rm.unicatt.it
Background: The aim of the study was to evaluate the outcome of acute myeloid leukaemia (AML) in patients with a previous malignancy (sAML) treated with chemo- and/or radiotherapy, enrolled in conventional trials.
Patients and methods: In a multicentre setting, a prospective non-concurrent analysis was performed on 2513 new AML patients, aged 12–78 years, consecutively enrolled in EORTC-GIMEMA trials between 1987 and 2001. Thirty-eight patients with sAML were identified and compared with a group of 114 de novo AML patients matched according to age, French–American–British criteria, white blood cell count at diagnosis, trial and time of diagnosis of AML. Induction treatment response, disease-free survival (DFS), duration and overall survival (OS) were evaluated in the two groups.
Results: Comparing the complete remission (CR) rate between 38 sAML patients and 114 de novo AML patients, selected according to the previously reported criteria, we observed no difference in the CR rates [25/38 (66%) versus 66/114 (58%); Pearson 
2 0.7393, P=0.390] as well as no differences while comparing the DFS and the OS between the two groups.
Conclusion: The results of this study suggest that sAML patients are characterised by a good performance status permitting their recruitment in conventional trials without a previous myelodysplastic phase. Similar to de novo AML patients, sAML patients show good response to treatment and the possibility of cure.
Key words: secondary acute myeloid leukaemia, treatment
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Fianchi, L. Pagano, F. Leoni, S. Storti, M. T. Voso, C. G. Valentini, S. Rutella, A. Scardocci, M. Caira, G. Gianfaldoni, et al. Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia Ann. Onc., January 1, 2008; 19(1): 128 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Palmieri, A. M. D'Arco, M. Celentano, G. Mele, C. Califano, F. Pollio, M. R. D'Amico, and F. Ferrara An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients Ann. Onc., July 1, 2006; 17(7): 1146 - 1151. [Abstract] [Full Text] [PDF]
|
|